BSF Enterprise PLC (LON: BSFA) has signed heads of terms with SCHAKAU Managementberatung GmbH for the worldwide exclusive commercialisation of its proprietary bioactive peptide ETSYL® across cosmetics, skincare, dermocosmetics and
ValiRx Secures Second European Patent for Cytolytix Cancer-Killing Peptide
ValiRx PLC (AIM: VAL) has received notice that the European Patent Office intends to grant a second patent covering the cancer-killing peptide being developed by its majority-owned subsidiary Cytolytix.
ImmuPharma Appoints Kymos Group to Support Kapiglucagon Development
ImmuPharma plc (AIM: IMM) has appointed Kymos Group as its bioanalytical contract research organisation partner for the development of Kapiglucagon, its proprietary glucagon prodrug for Type 1 diabetes applications.
Oxford Biomedica revenues rise as new client wins hit record
Oxford Biomedica (LON: OXB) has lowered its full-year 2026 revenue and profitability guidance after changes in customer ordering patterns and delays at its US facility, despite reporting record new client activity
MedPal AI Connects Pharmacy, Private Care and Software in a Rapid Growth Strategy
MedPal’s (AIM: MPAL) July trading update gave investors the clearest indication yet that its digital-health ambitions are being supported by real operating revenue. The company reported an annualised recurring revenue
Wellnex Life Shares Surge 84% on A$21.3 Million Pain Away Sale
Wellnex Life Limited (ASX/AIM: WNX) topped the market leaderboard after its shares surged 84% following the announcement of a binding agreement to sell its Pain Away business to Mentholatum Australasia for
Zak Mir Speaks to MedPal AI CEO Jason Drummond
Zak Mir talks to Jason Drummond, CEO of Medpal (AIM: MPAL), as the AI-native digital health and pharmacy group provided a trading update for July 2026, the first month in
MedPal AI Revenue Surges Above £8.6 Million After Record July
MedPal AI PLC (AIM: MPAL) shares rose 19% after the AI-powered digital health company reported a record July, with all three of its recurring revenue streams contributing to growth for
Genedrive Expands European Adoption with Erasmus MC Implementation
Genedrive PLC (AIM: GDR) has announced that its Genedrive® MT-RNR1 ID Kit has been implemented at Erasmus MC University Medical Center in Rotterdam, expanding the international adoption of its rapid
AstraZeneca Loses £15 Billion in Value on Bristol Myers Squibb Merger Report
More than £15 billion was wiped from AstraZeneca’s market value on Monday after reports that the pharmaceutical group has held talks over a potential US$400 billion merger with US rival
AstraZeneca Beats Second-Quarter Earnings Forecast
AstraZeneca PLC (LON: AZN, NASDAQ: AZN) reported better-than-expected second-quarter earnings as strong growth in oncology and rare diseases helped offset weaker sales in other parts of the business.
hVIVO Target Implies 270% Upside as Orderbook More Than Doubles
hVIVO’s order book has more than doubled to £65 million, prompting Shore Capital to reiterate its Buy rating and 25p target price.